Welcome, Guest. Please login or register.
October 19, 2019, 03:51:14 pm

Login with username, password and session length

  • Total Posts: 54508
  • Total Topics: 4644
  • Online Today: 65
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 1
Guests: 51
Total: 52


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Various Factors Tied to Lower Cure Rates for Epclusa And Mavyret  (Read 402 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 653
    • Hep Mag
Researchers identified an array of factors associated with a lower likelihood of being cured of hepatitis C virus (HCV) through treatment with Mavyret (glecaprevir/pibrentasvir) or Epclusa (sofosbuvir/velpatasvir) in a recent real-world study.

Presenting their findings at the 53rd International Liver Congress in Vienna, researchers analyzed data on 1,131 people with HCV who began Mavyret between August 2017 and April 2018 and were included in the Trio Health disease management program. The study also included 777 people who began Epclusa (sofosbuvir/velpatasvir) treatment during the same period.

For more...


© 2019 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.